Showing 81-90 of 4116 results for "".
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33
- Xeomin Injunction Stands; Another Hearing Scheduled for Tomorrowhttps://practicaldermatology.com/news/20120312-xeomin_injunction_stands_another_hearing_scheduled_for_tomorrow/2459848/Handing down his order as promised on Friday, US District Court Judge Andrew J. Guilford imposed a 10-month injunction barring Merz from selling or soliciting purchases of Xeomin®, in the US facial aesthetics market for 10 months. However, Judge Gui
- Low Cancer Risk Associated with UVA Nail Lampshttps://practicaldermatology.com/news/20120720-low_cancer_risk_associated_with_uva_nail_lamps/2459767/UVA lamps used for curing gel nails pose a very low risk for development of squamous cell carcinoma (SCC) on the dorsum of hands, new research suggests. (Br J Dermatol, E-pub). In fact, researchers say that only one woman in tens of thousands using UVA lamps over a number of years will develop SCC a
- Consensus Statement: JAK Inhibitors Emerge as Primary Therapy for Severe Alopeciahttps://practicaldermatology.com/news/consensus-statement-jak-inhibitors-emerge-as-primary-therapy-for-severe-alopecia/2488332/A US expert consensus provides a standardized treatment framework for adults with severe alopecia areata (AA), placing oral Janus kinase (JAK) inhibitors at the center of long-term disease management.
- Abrocitinib Responses Maintained Through Week 72 in JADE REALhttps://practicaldermatology.com/news/abrocitinib-responses-maintained-through-week-72-in-jade-real/2488053/New research suggests that flexible abrocitinib dosing under conditions designed to simulate clinical practice was associated with improvements through Week 72 among observed patients with moderate-to-severe atopic dermatitis (AD). Researchers for the JADE REAL trial enrolled 312 patients
- Researchers Recommend Refined Trial Design for Pediatric Vitiligo JAK Studieshttps://practicaldermatology.com/news/letter-highlights-trial-design-considerations-in-pediatric-vitiligo/2487858/Correspondence in the Journal of the American Academy of Dermatology asked for caution when interpreting findings from a recent trial evaluating oral Janus kinase (JAK) inhibitors in combination with 308-nm excimer laser th
- Study: JAK Inhibitor–Excimer Laser Combination Improves Repigmentation in Pediatric Vitiligohttps://practicaldermatology.com/news/jak-inhibitorexcimer-laser-combination-improves-repigmentation-in-pediatric-vitiligo-trial/2487301/Children with progressive vitiligo treated with an oral Janus kinase (JAK) inhibitor combined with 308-nm excimer laser therapy experienced significantly greater repigmentation than those treated with topical tacrolimus and excimer laser therapy, according to
- Analysis: Pediatric Allergic Rhinitis Doubled in Japan Over 40 Yearshttps://practicaldermatology.com/news/analysis-pediatric-allergic-rhinitis-doubled-in-japan-over-40-years/2487238/A 40-year epidemiologic analysis published in the World Allergy Organization Journal showed an increases in allergic rhinitis (AR), allergic conjunctivitis (AC), and Japanese cedar pollinosis (JCP) among school-aged children in western Japan, while rates of atopic dermatitis (AD) and bro
- Ultrasound Detects Subclinical Joint and Nail Changes in Pediatric Psoriasishttps://practicaldermatology.com/news/ultrasound-detects-subclinical-joint-and-nail-changes-in-pediatric-psoriasis/2487206/Musculoskeletal ultrasound may help identify early inflammatory changes in children with psoriasis before the onset of clinically apparent arthritis, according to findings from a pilot study evaluating joint, entheseal, and nail abnormalities in pediatric patients.
- Dr. James Del Rosso Presents ‘Medicine Chest’ at Winter Clinical 2026https://practicaldermatology.com/news/dr-james-del-rosso-presents-medicine-chest-at-winter-clinical-2026/2485373/James Q. Del Rosso, DO, delivered his annual “What’s New in the Medicine Chest” update at the 2026 Winter Clinical Dermatology Conference, covering new therapies, novel data, and practice-changing pearls spanning from molluscum and hyperhidrosis to vitiligo, lichen planus, and even mastocytosis.<